- Home
- HRMY vs BUSE Comparison
HRMY vs BUSE Comparison
Compare HRMY & BUSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HRMY | BUSE |
|---|---|---|
| Founded | 2017 | 1868 |
| Country | United States | United States |
| Employees | N/A | 1914 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.5B |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | HRMY | BUSE |
|---|---|---|
| Price | $42.11 | $30.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $44.11 | $27.17 |
| AVG Volume (30 Days) | ★ 603.1K | 586.8K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | ★ 4.04% |
| EPS Growth | ★ 7.97 | N/A |
| EPS | ★ 1.84 | 1.20 |
| Revenue | ★ $868,453,000.00 | $719,584,000.00 |
| Revenue This Year | $19.75 | $23.84 |
| Revenue Next Year | $12.88 | $3.82 |
| P/E Ratio | ★ $23.20 | $25.56 |
| Revenue Growth | 21.51 | ★ 55.66 |
| 52 Week Low | $25.52 | $22.00 |
| 52 Week High | $43.49 | $31.70 |
Technical Indicators
Market Signals| Indicator | HRMY | BUSE |
|---|---|---|
| Relative Strength Index (RSI) | 69.47 | 55.27 |
| Support Level | $34.87 | $30.61 |
| Resistance Level | N/A | $31.70 |
| Average True Range (ATR) | 1.24 | 0.48 |
| MACD | 0.29 | -0.05 |
| Stochastic Oscillator | 86.77 | 55.79 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About BUSE First Busey Corporation
First Busey Corporation is a financial holding company whose subsidiaries provide retail and commercial banking services, remittance processing, and offer financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech, and Wealth Management. The banking segment generates a vast majority of its revenue.